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agents clopidogrel and prasugrel. METHODS: We developed a decision model to 
evaluate the potential clinical beneﬁts and harms for three strategies—clopidigrel, 
prasugrel, and genotype-guided therapy—used for the treatment of patients with acute 
coronary syndromes with planned percutaneous coronary intervention. Data were 
derived from the published literature, including the TRITON-TIMI 38 trial, and 
publicly available sources. The lifetime incidence of clinical events was projected, and 
net health beneﬁt assessed using quality-adjusted life-years. Sensitivity and scenario 
analyses were conducted to assess uncertainty in results. RESULTS: Compared to 
clopidogrel therapy, prasugrel therapy was signiﬁcantly associated with an average 
incremental decrease in the lifetime risk of myocardial infarction, but also an average 
incremental increase in the risk of major bleed events and bleed deaths. The genotype-
guided treatment strategy did not exhibit any statistically signiﬁcant difference in the 
population risk of clinical events when compared to the clopidogrel and prasugrel 
strategies. No signiﬁcant differences in net beneﬁts were demonstrated among treat-
ment strategies. The nonvariant clopidogrel therapy population and the prasugrel 
therapy population had signiﬁcantly favorable cardiovascular and life expectancy 
outcomes compared to the CYP2C19 reduced-function allele population undergoing 
clopidogrel therapy. CONCLUSIONS: The inherent beneﬁt-harm tradeoff of anti-
platelet agents could potentially be improved with the use of CYP2C19 genotype 
information in patients with acute coronary syndrome. Genotype-guided therapy leads 
to improved outcomes for reduced-function CYP2C19 individuals, however this 
approach does not result in signiﬁcant differences for the aggregate acute coronary 
syndrome population when compared to the overall clopidogrel and prasugrel therapy 
strategies. Ongoing randomized controlled trials will be critical in further assessing 
the role of the CYP2C19 reduced function allele when deciding optimal antiplatelet 
treatment regimens.
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OBJECTIVES: The object of analysis is the presentation of results from the Heart-
Vessel Diseases Prophylactic Program for 40 and 50 year old residents of Wroclaw 
conducted from 1998 to 2008. 43 thousand people took part in the program. The 
aim of the program was to counteract health, life and disability risks which are among 
of the main causes of death in Poland—heart-vessel diseases as well as primary and 
secondary prevention and analysis of the appearance of the risk factors of these dis-
eases. METHODS: Outcomes analysis was used to evaluate the program. The analysis 
was carried out on the health results of two groups of participants of the program. 
The ﬁrst group comprised of 50 year old people invited to the program for the ﬁrst 
time. The second group comprised of the 50 year old participants who had already 
taken part in the program 10 years earlier. The participants of the program underwent 
health education concerning prophylactics of heart-vessel diseases and they were 
presented with coefﬁcients such as BMI, triglyceride levels, cholesterol, glucose and 
blood pressure. A health proﬁle was made for every participant. RESULTS: The health 
situation changed in almost 1/3 of the people in the group that took part in the 
program 10 years ago. The modiﬁable risk factors of heart vessel diseases underwent 
changes: an increase in protein intake (36%), increased physical activity (27%) as well 
as carrying out systematic blood sugar controls (22%).11% of the participants of the 
program, who were analyzed for the second time, thought that the health education 
carried out then, affected their life styles to a greater extent. CONCLUSIONS: After 
evaluation period of 10 years, efﬁciency of program and activities were analyzed and 
shown. Outcome analysis veriﬁed that 10 years of prophylactic program, reduced 
exposure to risk factor of DOTCS. We also selected an areas for future modiﬁcation 
and improvement. Due to outcomes analysis, regional politics of health protection 
was adequate to epidemiological factors and social needs of regions.
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OBJECTIVES: Coronary heart disease (CHD) mortality has declined substantially in 
Canada over recent decades. Our objective was to determine what proportion of this 
decline was associated with temporal trends in CHD risk factors and advancements in 
medical treatments. METHODS: The validated IMPACT model was used for all analy-
ses, integrating data on population size, CHD mortality, in addition to risk factor and 
treatment uptake changes in adults 25 years and older between 1994 and 2005 in 
Ontario. Relative risks and regression coefﬁcients from the published literature quanti-
ﬁed the relationship between CHD mortality and a) evidence-based therapies in 8 dis-
tinct CHD sub-populations (acute myocardial infarction (AMI), acute coronary 
syndromes, secondary prevention post-AMI, chronic angina/CHD, in-hospital, heart 
failure, community heart failure, and 1° prevention for hyperlipidemia or hypertension) 
and b) population trends in 6 risk factors (smoking, diabetes mellitus, systolic blood 
pressure, plasma cholesterol, exercise, and obesity). The outcome of interest was the 
number of deaths prevented or postponed. RESULTS: From 1994–2005, the age-
adjusted CHD mortality rate in Ontario fell 35% from 190.9 to 124.8 deaths per 
100,000 inhabitants, translating to an estimated 7585 fewer CHD deaths in 2005. 
Improvements in medical treatments accounted for approximately 43% of the total 
mortality decrease, most notably in AMI (9%), chronic angina (17%) and community 
heart failure (10%). Trends in risk factors explained approximately 48% % of the total 
mortality decrease, speciﬁcally reductions in plasma cholesterol (23%), and systolic 
blood pressure (20%). Increasing diabetes prevalence and body mass index had a nega-
tive impact, increasing CHD mortality by approximately 6% and 2%, respectively. 
CONCLUSIONS: Our results suggest that future CHD strategies should maximise 
evidence-based therapies and support more aggressive policies to promote healthy diets.
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OBJECTIVES: The purpose of this study was to evaluate the relative efﬁcacy and 
safety of dalteparin against anticoagulant therapies in patients with: cancer, medical 
patients at risk of VTE, total hip replacement, and acute myocardial infarction (AMI). 
METHODS: A meta-analysis was performed with randomized clinical trials (RCT) 
where anticoagulant therapies were used to prevent or treat VTE. Effectiveness was 
assessed with the reduction in pulmonary thromboembolism(PE) and deep vein throm-
bosis (DVT) events; safety with the frequency and type of adverse events(AE). RCT 
were searched in December 2008 in Medline, EMBASE and the Cochrane Collabora-
tion. Two independent reviewers identiﬁed the abstracts, selected the full articles and 
extracted data. Odds ratios and weighted means differences were calculated. Random 
effects models were employed in the analyses. RESULTS: From 2,539 abstracts, we 
obtained 91 RCT, 23 were excluded (unacceptable designs, insufﬁcient outcome data) 
leaving 68. Dalteparin(2500–7500 IU/day) was compared against unfractioned 
heparin, enoxaparin, warfarin, nadroparin, fondaparinux, aspirin and placebo. In 
patients with AMI, dalteparin showed to be effective in diminishing new infarctions 
and death (OR 0.66; 95%CI 0.33–0.99) or revascularizations (OR 0.76; 0.57–1.01). 
In total hip replacement patients, dalteparin showed reduction in DVT (OR 0.47; 
0.38–0.60) but not in PE (OR: 0.45; 0.09–2.39). In comparison to placebo, the 
number of deaths were lower (OR 0.14; 0.02–1.27). In patients with VTE no statistical 
differences were found against competing alternatives, as well as in thromboembolism, 
thrombosis progression and death. Finally, in cancer patients, dalteparin showed to 
be effective in diminishing DVT(OR 0.39; 0.22–0.68) but not differences in reducing 
mortality (OR 0.92; 0.73–1.17); major bleeding(OR 1.20; 0.48–2.98) or minor bleed-
ing (OR 0.87; 0.41–1.83). CONCLUSIONS: Dalteparin is an effective low-molecular-
weight heparin in the prevention and treatment of VTE in surgery and non surgery 
patients, not showing higher AE than unfractioned heparin or other recommended 
therapies.
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OBJECTIVES: Diabetes patients with coronary artery disease represent a population 
with high cardiovascular morbidity and mortality. The objective of the study was to 
compare the long-term effectiveness of percutaneous coronary intervention (PCI) 
versus coronary artery bypass graft (CABG) in diabetic patients with multi-vascular 
coronary artery disease (MVD). METHODS: Studies were retrieved from PUBMED 
database using keywords: angioplasty, coronary, stent, PCI and coronary artery 
bypass surgery (August 1992 to December 2009). Randomised controlled trials which 
compared PCI and CABG in head to head comparisons were included according to 
pre-speciﬁed inclusion/exclusion criteria. The outcomes of interest were mortality, 
myocardial infarction (MI), stroke, and the use of additional revascularization proce-
dures. Two reviewers independently extracted data from the included studies. Data 
was analyzed using STATA (v9.0).RESULTS: Of the 416 studies identiﬁed, 5 studies 
met the inclusion criteria. A total of 813 patients were included in this analysis (208 
in ARTS, 78 in EARCI-II, 115 in MASS-II, 353 in BARI trial, and 59 in EAST). In 
total, 409 diabetic patients with MVD were randomized to PCI, and 404 were ran-
domized to CABG. Survival was signiﬁcantly greater after CABG than after PCI with 
a risk ratio of 1.28 (95% CI 1.06, 1.55); p = 0.009 for the ﬁve-year mortality rate. 
The relative risk for revascularization rate at ﬁve year follow-up was 4.11 (95% CI: 
2.20, 7.68) for PCI vs. CABG. Results for myocardial infarction were non-signiﬁcant 
with a risk ratio of 1.10 (95% CI: 0.73, 1.65); p = 0.644. CONCLUSIONS: CABG 
was associated with lower incidence of mortality and revascularization at ﬁve years 
of follow-up compared to PCI. Rate of MI was similar for both the procedures. 
Analysis from this review suggests that CABG greatly improves survival and re-
intervention rate when compared to PCI, in diabetic patients with multi-vessel coro-
nary artery disease.
